Search results
Velazquez E.M., Mendoza S., Hamer T., Sosa F., Glueck C.J. (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43: 647–654 [Google Scholar]
- PMC Free Article
TYPE 2 diabetes mellitus, formerly called...
- PubMed
The classification of diabetes mellitus and the tests used...
- PMC Free Article
1 gru 2022 · Metformin is typically the first-line treatment for patients with type 2 diabetes; it is not approved for use in prediabetes or PCOS, although it is often prescribed for treatment of these conditions.
4 sie 2022 · Treatment focuses on reducing hyperandrogenism symptoms, restoring menstrual regularity, and achieving conception. In treating infertility caused by polycystic ovarian syndrome, letrozole (an aromatase inhibitor) appears to be more successful than clomiphene citrate (an anti-estrogen and a reference infertility drug).
15 kwi 2014 · Metformin is an effective ovulation induction agent for non-obese women with PCOS and offers some advantages over other first line treatments for anovulatory infertility such as clomiphene. For clomiphene-resistant women, metformin alone or in combination with clomiphene is an effective next step.
20 lis 2023 · 1 INTRODUCTION. Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women worldwide affecting one out of eight regardless of ethnic background. 1, 2 Apart from the symptoms included in the diagnostic criteria (hyperandrogenism and menstrual cycle irregularity), clinical manifestations include reproductive, cardiometabolic, dermatological and psychological features. 3 ...
23 paź 2003 · This is the first systematic review and meta-analysis of randomised controlled trials in the use of metformin in treating polycystic ovary syndrome. Where metformin is used as a sole agent, ovulation is achieved in 46% of recipients compared with 24% in the placebo arm (NNT = 4.4)
3 sty 2008 · Strategies for long-term metformin therapy in patients with the polycystic ovary syndrome are evolving, and the identification of predictors of the response to metformin, possibly even...
